Paper Review Records
All Paper Review Records
10 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
66
days
MiR-590 suppresses the progression of non-small cell lung cancer by regulating YAP1 and Wnt/β-catenin signaling
AuthorsX. Hao; A. Su
Affiliations1. Department of Internal Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China; 2. General Department, Bejing Chaoyang District Sanhuan Cancer Hospital, Beijing, China
70
days
Human umbilical cord mesenchymal stem cell-derived exosomes carrying hsa-miRNA-128-3p suppress pancreatic ductal cell carcinoma by inhibiting Galectin-3
AuthorsX. Xie; J. Ji; X. Chen; W. Xu; H. Chen; S. Zhu; J. Wu; Y. Wu; Y. Sun; W. Sai; Z. Liu; M. Xiao; B. Bao
Affiliations1. Department of Gastroenterology, Affiliated Hospital and Medical School of Nantong University, Nantong, China; 2. Office of Infection Management, Affiliated Hospital of Nantong University, Nantong, China; 3. Department of Gastroenterology, Second People’s Hospital of Nantong, Nantong, China; 4. Medical School of Nantong University Oral Medicine, Nantong, China; 5. Blood Center of Jiangsu Province, Nanjing, China; 6. Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, China
46
days
Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines
AuthorsP. García-Alfonso; M. Saiz-Rodríguez; R. Mondéjar; J. Salazar; D. Páez; A. M. Borobia; M. J. Safont; I. García-García; R. Colomer; X. García-González; M. J. Herrero; L. A. López-Fernández; F. Abad-Santos
Affiliations1. Medical Oncology Department, Hospital General Universitario Gregorio Marañón, Sociedad Española de Oncología Médica (SEOM), Madrid, Spain; 2. Research Unit, Fundación Burgos por la Investigación de la Salud (FBIS), Hospital Universitario de Burgos, Sociedad Española de Farmacogenética y Farmacogenómica (SEFF), Burgos, Spain; 3. Medical Oncology Service, Hospital Universitario de la Princesa, Sociedad Española de Oncología Médica (SEOM), Madrid, Spain; 4. Research Institute of Hospital de la Santa Creu I Sant Pau, Sociedad Española de Farmacogenética y Farmacogenómica (SEFF), Barcelona, Spain; 5. Medical Oncology Department, Hospital de la Santa Creu I Sant Pau, Sociedad Española de Oncología Médica (SEOM), Barcelona, España; 6. Clinical Pharmacology Service, Hospital Universitario La Paz, Sociedad Española de Farmacogenética y Farmacogenómica (SEFF), Madrid, Spain; 7. Medical Oncology Service, Consorcio Hospital General Universitario de Valencia, Universidad de Valencia, CIBERONC, Sociedad Española de Oncología Médica (SEOM), Valencia, Spain; 8. Medical Oncology Service, Hospital Universitario de La Princesa y Cátedra de Medicina Personalizada de Precisión de la Universidad Autónoma de Madrid (UAM), Sociedad Española de Oncología Médica (SEOM), Madrid, Spain; 9. Hospital Pharmacy Service, Hospital General Universitario Gregorio Marañón, Sociedad Española de Farmacogenética y Farmacogenómica (SEFF), Madrid, Spain; 10. Pharmacogenetics Platform, IIS La Fe-Hospital La Fe and Pharmacology Department, Universidad de Valencia, Sociedad Española de Farmacogenética y Farmacogenómica (SEFF), Valencia, Spain; 11. Clinical Pharmacology Service, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, Sociedad Española de Farmacogenética y Farmacogenómica (SEFF), Madrid, Spain
56
days
Tumor immune microenvironment is influenced by frameshift mutations and tumor mutational burden in gastric cancer
AuthorsH. Kim; Y. J. Heo; Y. A. Cho; S. Y. Kang; S. Ahn; K. -M. Kim
Affiliations1. Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; 2. The Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; 3. Department of Pathology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Republic of Korea
50
days
Identification of a novel cancer microbiome signature for predicting prognosis of human breast cancer patients
AuthorsA. W. Mao; H. Barck; J. Young; A. Paley; J. -H. Mao; H. Chang
Affiliations1. Berkeley Biomedical Data Science Center, Lawrence Berkeley National Laboratory, Berkeley, USA; 2. Biological Systems and Engineering Division, Lawrence Berkeley National Laboratory, Berkeley, USA
92
days
PD1/PDL1 expression is associated with increased TIM3 expression and tumor-infiltrating T lymphocytes in fibroblastic tumors
AuthorsH. Chen; H. Liu; J. Ai; X. Du; Y. Sun; S. Xiao
Affiliations1. Department of Laboratory Medicine, The Second Affiliated Hospital of Guilin Medical University, Guilin, China; 2. Guangxi Health Commission Key Laboratory of Glucose and Lipid Metabolism Disorders, The Second Affiliated Hospital of Guilin Medical University, Guilin, China; 3. Department of Pathology, The Second Affiliated Hospital of Guilin Medical University, Guilin, China; 4. Department of Neurobiology, College of Life Sciences, Wuhan Institute for Neuroscience and Neuroengineering, South-Central University for Nationalities, Wuhan, China
16
days
Future care for long-term cancer survivors: towards a new model
AuthorsM. Provencio; N. Romero; J. Tabernero; R. Vera; D. V. Baz; A. Arraiza; C. Camps; E. Felip; P. Garrido; B. Gaspar; M. Llombart; A. López; I. Magallón; V. M. Ibáñez; J. M. Olmos; C. Mur; A. Navarro-Ruiz; A. Pastor; M. Peiró; J. Polo; Á. Rodríguez-Lescure
Affiliations1. Medical Oncology Department, Spanish Lung Cancer Group (GECP), Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain; 2. Cardiology and Cardiac Surgery Clinical Management Unit, Hospital Virgen del Rocio, Sevilla, Spain; 3. Medical Oncology Department, Hospital Universitario Vall d’HebronVHIOEuropean Society for Medical Oncology (ESMO), Barcelona, Spain; 4. Medical Oncology Department, Complejo Hospitalario de NavarraServicio Navarro de la SaludSpanish Society of Medical Oncology (SEOM), Navarra, Spain; 5. Medical Oncology Department, Hospital Universitario Virgen Macarena, Andalusian Comprehensive Oncology Plan, Sevilla, Spain; 6. Health Programmes, Health Care, Osakidetza, País Vasco, Spain; 7. Medical Oncology Department, Hospital General Universitario de ValenciaUniversidad de Valencia CIBERONCECO Foundation, Valencia, Spain; 8. Institut d’Oncologia, Vall d’Hebron University Hospital, Spanish Society of Medical Oncology (SEOM), Barcelona, Spain; 9. Department of Medical Oncology, IRYCIS, Hospital Universitario Ramón y Cajal, Spanish Society of Medical Oncology (SEOM), Madrid, Spain; 10. Spanish Association of Lung Cancer Patients (AEACaP), Valencia, Spain; 11. Valencia Oncology Institute Foundation, Valencia, Spain; 12. Pharmacy, Navarra Health Service—Osasunbidea, Navarra, Spain; 13. Medical Oncology Department, Hospital Universitario Vall d’Hebron, Spanish Oncology Nursing Society (SEEO), Barcelona, Spain; 14. Professional Organization of the Ministry of Health, Madrid, Spain; 15. Senate Health Committee, Andalusian School of Public Health, Granada, Spain; 16. Clínicas CAT Barcelona, Spanish Society of Health Directors (SEDISA), Barcelona, Spain; 17. Hospital Pharmacy ServiceHospital General Universitario de ElcheSpanish Society of Hospital Pharmacy, Alicante, Spain; 18. Spanish Society of Family and Community Medicine (SEMFyC), Madrid, Spain; 19. Universitat Ramon Llull, ESADE, Barcelona, Spain; 20. Centro de Salud Casar de Cáceres, Spanish Society of Primary Care Physicians (SEMERGEN), Cáceres, Spain; 21. Medical Oncology Department, Hospital General Universitario de Elche, Spanish Society of Medical Oncology (SEOM), Alicante, Spain
89
days
Linezolid-induced thrombocytopenia in patients with acute myeloid leukemia: a matched case–control study
AuthorsCan Chen; Yiwei Li; Jingdi Yu; Shenxian Qian
Affiliations1. Department of Hematology, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China; 2. Department of Critical Care Medicine, Hangzhou First People’s Hospital Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
39
days
High-dose-rate plesiotherapy with customized molds in non-melanoma skin cancer: efficacy and safety at 10 years—single institution experience
AuthorsI. Membrive Conejo; O. Pera Cegarra; P. Foro Arnalot; A. Reig Castillejo; N. Rodríguez de Dios; X. Sanz Latiesas; G. Deza; J. Quera Jordana; E. Fernandez-Velilla Cepria; A. Martínez Moñino; F. Liu Cheng; M. Algara López
Affiliations1. Radiation Oncology Department, Hospital del Mar, Barcelona, Spain; 2. Institut Hospital del Mar d’Investigacions Mèdiques Barcelona, Barcelona, Spain; 3. Pompeu Fabra University, Barcelona, Spain; 4. Dermatology Department, Hospital del Mar, Barcelona, Spain; 5. Universitat Autónoma de Barcelona, Barcelona, Spain
54
days
Expressions of PD-L1 and Nectin-4 in urothelial cancer patients treated with pembrolizumab
AuthorsH. Ueki; N. Hinata; K. Kitagawa; T. Hara; T. Terakawa; J. Furukawa; K. Harada; Y. Nakano; M. Komatsu; M. Fujisawa; T. Shirakawa
Affiliations1. Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan; 2. Department of Advanced Medical Science, Kobe University Graduate School of Science, Technology and Innovation, Kobe, Japan; 3. Department of Diagnostic Pathology, Kobe University Graduate School of Medicine, Kobe, Japan
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days